Lilly is setting up a voluntary Forteo patient registry to collect data on potential bone cancer risk as part of FDA's approval of a new indication for the osteoporosis treatment. The company is also instituting a Risk Evaluation and Mitigation Strategy to control for the risk. On July 22, FDA expanded use of the injectable drug to include treatment of glucocorticoid-induced osteoporosis (GIO) in adult patients at high risk for fracture. The labeling for Forteo (teriparatide) has included a boxed...